Skip to content

Corcept Therapeutics

US · CORT #1285 by market cap Listed 1970
63.62 -1.36 -2.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
74.20% -0.06pp
Institutions
584 -2
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund56.75%
Hedge Fund12.04%
Individual/Insider10.54%
Private Company1.66%
Public Company1.33%
Government Pension Fund1.06%
Sovereign Wealth Fund0.45%
VC/PE Fund0.41%
Insurance Company0.29%
Other15.46%

Top holders as of 2026-09-30

BlackRock 9.32% · 10.20M sh
Ingalls & Snyder, LLC 7.01% · 7.67M sh
George Baker 5.07% · 5.55M sh
Vanguard Capital Management, LLC 4.54% · 4.97M sh
Renaissance Technologies Corp. 4.43% · 4.85M sh
Vanguard Portfolio Management, LLC 4.36% · 4.78M sh
Parallel Advisors, LLC 3.57% · 3.90M sh
AQR Capital Management 3.29% · 3.60M sh
FMR 3.19% · 3.49M sh
Joseph Belanoff 2.62% · 2.87M sh
State Street Global Advisors 2.84% · 3.10M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 10 buys · 35 sells

NameRoleStake
George Baker Independent Director 5.07%
Joseph Belanoff Chief Executive Officer 2.62%
James Wilson Independent Chairperson 1.32%
David Mahoney Independent Director 1.06%
Hazel Hunt Chief Scientific Officer 0.23%
Sean Maduck Former President of Endocrinology 0.12%
Gary Robb Chief Business Officer & Secretary 0.09%
Atabak Mokari Chief Financial Officer 0.01%
Joseph Lyon Chief Technology & Accounting Officer 0.01%
Justin Gunn President of Endocrinology 0.00%
William Guyer Chief Development Officer 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Daniel Swisher Independent Director Derivative Exercise and Sale -1,500 $10.50–74.07
2026-11-02 Sean Maduck Former President of Endocrinology Derivative Exercise and Sale -25,000 $8.27–82.68
2026-11-01 Roberto Vieira President of Oncology Derivative Exercise and Sale -8,333 $21.63–81.52
2026-10-14 James Wilson Independent Chairperson Automatic Disposition -10,000 $114.48–116.30
2026-10-01 Sean Maduck Former President of Endocrinology Derivative Exercise and Sale -25,000 $8.27–116.55
2026-10-01 Joseph Lyon Chief Technology & Accounting Officer Derivative Exercise and Sale -10,000 $13.56–116.54
2026-10-01 Roberto Vieira President of Oncology Derivative Exercise and Sale -8,333 $21.63–116.59
2026-09-30 Joseph Lyon Chief Technology & Accounting Officer Intent to Sell (Form 144) -10,000 $115.23
2026-09-30 Justin Gunn President of Endocrinology Other Derivative Acquisition +100,000 $114.03
2026-09-30 Justin Gunn President of Endocrinology Initial Statement of Beneficial 0 --
2026-09-23 Gary Robb Chief Business Officer & Secretary Other Acquisition +10,000 --
2026-09-23 Gary Robb Chief Business Officer & Secretary Other Disposition -17,100 --
2026-09-16 Gary Robb Chief Business Officer & Secretary Derivative Exercise and Retained +17,493 $8.27
2026-09-15 Roberto Vieira President of Oncology Automatic Disposition -296 $100.82
2026-09-14 James Wilson Independent Chairperson Automatic Disposition -10,000 $110.27–111.70
2026-09-13 Joseph Lyon Chief Technology & Accounting Officer Derivative Exercise and Sale -10,000 $11.35–114.12
2026-09-01 Atabak Mokari Chief Financial Officer Sale to Issuer -102 $113.38
2026-09-01 Gary Robb Chief Business Officer & Secretary Sale to Issuer -91 $113.38
2026-09-01 Sean Maduck Former President of Endocrinology Sale to Issuer -117 $113.38
2026-09-01 Joseph Lyon Chief Technology & Accounting Officer Sale to Issuer -72 $113.38

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Corcept Therapeutics discussion 0 comments

Add a comment